The 11 most recent market catalysts affecting $ERAS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 75
Erasca Announces FDA Granted Fast Track Designation To ERAS-0015 For Metastatic Pancreatic Adenocarcinoma
The FDA's Fast Track designation for ERAS-0015 is a substantial positive for Erasca, as it implies an expedited review process and more frequent communication with the FDA, potenti…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22
HC Wainwright & Co. analyst Andres Y. Maldonado has maintained a 'Buy' rating on Erasca (ERAS) and raised the price target from $18 to $22. This action signals increased confidence…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 92
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Erasca's Q2 earnings report revealed a loss of $(0.14) per share, which was a substantial miss compared to the analyst consensus of $(0.11). This 27.27% miss, coupled with a 16.67%…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 85
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
Erasca (ERAS) announced updated preliminary Phase 1 data for its cancer candidate ERAS-0015, showing encouraging early activity in RAS-mutant solid tumors, particularly a 57% uncon…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 75
Erasca shares are trading higher after B of A Securities raised its price target on the stock from $16 to $18. The company announced the pricing of its upsized public offering of 31,428,572 shares at $17.50 per share.
This headline is a significant positive catalyst for Erasca. The raised price target from a major investment bank like B of A Securities signals increased analyst confidence in the…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
B of A Securities Maintains Neutral on Erasca, Raises Price Target to $18
BofA Securities analyst Alec Stranahan maintained a 'Neutral' rating on Erasca (ERAS) but raised the price target from $16 to $18. This action reflects a slightly improved valuatio…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Erasca Announces Pricing Of Upsized Public Offering Of 31,428,572 Common Shares At $17.50 Per Share
This headline signals a significant capital raise for Erasca, a biotechnology company. The upsized offering and specific pricing at $17.50 per share, likely below the previous mark…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 85
Erasca shares are trading lower after the company announced a $500 million offering. The company filed a prospectus for a mixed-shelf offering.
The announcement of a $500 million mixed-shelf offering by Erasca is a significant negative catalyst for the company's stock. A mixed-shelf offering allows a company to issue vario…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 75
Erasca Plans To Commence $500M Common Stock Offering
Erasca, a clinical-stage precision oncology company, is planning a substantial $500 million common stock offering, with an additional $75 million option for underwriters. This capi…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 55
Erasca Files Prospectus For Offering Mixed Shelf; Terms Undisclosed
Erasca filed a Form S-3 ASR, which is an automatic shelf registration statement. This allows the company to offer and sell an unspecified amount of common stock, preferred stock, d…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 85
Erasca Announces Updated Preliminary ERAS‑0015 Phase 1 Data And Clinical Plans, With Pivotal Lung And Pancreatic Cancer Trials Slated For 2027
Erasca has released updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing a 57% unconfirmed objective response rate (uORR) in second-line or later KRAS…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.